Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors
Authors:
- Yaakov E. SternYSYaakov E. Stern
- Pompom GhoshPGPompom Ghosh
- John PerozaJPJohn Peroza
- Hitendra S. SolankiHSHitendra S. Solanki
- Denis ImbodyDIDenis Imbody
- Liznair BridenstineLBLiznair Bridenstine
- Thiyagamurthy PanduranganTPThiyagamurthy Pandurangan
- Sylvia M. FrydmanSFSylvia M. Frydman
- Kathryn N. NickensKNKathryn N. Nickens
- Hannah L. Walker-MimmsHWHannah L. Walker-Mimms
- Kruthi SuvarnaKSKruthi Suvarna
- Neelkamal ChaudharyNCNeelkamal Chaudhary
- 30 October 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (2) , 485-502
Abstract
The onset of acquired resistance limits the efficacy of KRASG12C inhibitors in patients with lung cancer. Experiments in preclinical model systems and retrospective analyses of patients treated with these inhibitors have both suggested that the activation of DNA repair pathways and G2/M kinases is common in lung cancers with acquired resistance to KRASG12C inhibitors. In this study, we identified a shared vulnerability to the CDK12/13-selective inhibitor SR-4835 in several KRASG12C-mutant cell lines with acquired resistance to sotorasib. In pairs of KRASG12C-mutant parental and sotorasib-resistant cell lines, CDK12/13 inhibition suppressed DNA repair gene expression and induced mitotic arrest, which was exacerbated in sotorasib-resistant cells by failure to activate the G2/M checkpoint and suppression of an oncogenic isoform of TP73. Combined treatment with both sotorasib and SR-4835 yielded an additive response and suppressed the development of acquired resistance to either inhibitor. The inhibitor combination caused additive G1 and G2/M arrest, and the increased sensitivity of emerging drug-resistant cell populations to SR-4835 extended the duration of response over single-agent treatment in cell culture and mouse models. These results support combining KRAS and CDK12/13 inhibitors to extend the duration of response in KRAS-mutant lung cancer. Patients with acquired resistance to sotorasib may benefit from follow-up monotherapy with CDK12/13 inhibitors, the first of which, recently entered clinical trials. Targeting CDK12/13 thus offers a promising strategy to overcome or prevent resistance to KRAS inhibitors. Significance: CDK12/13 is an effective target to prevent the development of acquired resistance to KRASG12C inhibitors and to treat cancers that have developed resistance, providing a combinatorial approach for optimizing KRAS-mutant tumor treatment. See related article by Solanki et al., p. 467Keywords
Funding Information
- National Cancer Institute (5R01CA262530-0)
This publication has 48 references indexed in Scilit:
- Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutationsCell Reports Medicine, 2024
- Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancerCancer Cell, 2024
- Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trialThe Lancet, 2023
- SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening DatasetsGenomics, Proteomics & Bioinformatics, 2022
- Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast CancerCancer Cell, 2019
- Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancerBioorganic & Medicinal Chemistry, 2018
- Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancerInternational Journal of Cancer, 2017
- The Molecular Signatures Database Hallmark Gene Set CollectionCell Systems, 2015
- Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency ModelComputational and Structural Biotechnology Journal, 2015
- Aurora Kinase-A Inactivates DNA Damage-Induced Apoptosis and Spindle Assembly Checkpoint Response Functions of p73Cancer Cell, 2012